2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Bi-Specific MAbS Market?

The expected growth in the bispecific monoclonal antibodies market is predicted to be driven by the rising incidence of cancer and various other chronic illnesses. These particular antibodies are used in the treatment of several conditions like cancer, infectious diseases, disorders related to the central nervous system, and autoimmune diseases. Compared to monoclonal antibodies (moAbs), bispecific monoclonal antibodies are believed to be more effective, as they target multiple tumor antigens on cells to inhibit cancer progression. To illustrate, the Cancer Facts & Figures 2023 report from the American Cancer Society (ACS), a voluntary health organization in the US, predicts about 609,820 cancer-related fatalities in the USA by 2023. Consequently, the increased prevalence of chronic conditions, including cancer, is likely to boost the demand for bispecific monoclonal antibodies for a more effective treatment.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

#What Long-Term Growth Rate is Expected for theBi-Specific MAbS Market Between 2025 and 2034?

The market size for bi-specific MAbS has seen substantial growth recently and is predicted to expand from $7.83 billion in 2024 to $9.1 billion in 2025 with a compound annual growth rate (CAGR) of 16.2%. This progress during the historic period is largely due to the rise in healthcare spending, amplified funding, and initiatives from the government.

The market for bi-specific MAbS is anticipated to experience a fast-paced expansion over the coming years. The market size is projected to reach $15.19 billion by 2029, with a compound annual growth rate (CAGR) of 13.7%. This growth during the forecasted period can be linked to the rising incidence of cancer, an aging population, and a growth in chronic disease cases. In the prediction period, prevalent trends involve emphasis on technological progress, product innovation, the application of artificial intelligence, investments in targeted and combination treatments, as well as strategic collaborations.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3390

What Are the Key Market Innovations in theBi-Specific MAbS Market Over the Coming Years?

In an attempt to widen their product offering and extend their geographic reach, businesses in the bi-specific MAbs industry are progressively putting their resources into strategic endeavors, such as alliances and partnerships. A strategic partnership occurs when two or more firms work cooperatively to achieve shared aims or goals. To illustrate, Gilead Sciences and MacroGenics, both biopharmaceutical firms based in the US, forged an exclusive alliance in October 2022. The partnership aims to develop MGD024, a bispecific antibody targeting CD123 and CD3, using MacroGenics’ DART platform, in conjunction with two other bispecific research initiatives. This partnership gives Gilead the exclusive right to license MGD024, which shows promise in treating a variety of hematologic cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 has been engineered to reduce cytokine-release syndrome (CRS), allowing for intermittent dosing, which could potentially result in a more patient-oriented approach to treatment and better clinical results for those suffering from AML and MDS.

Who Are the Top Companies Driving Innovation and Growth in theBi-Specific MAbS Market?

Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

Which Key Market Segments Comprise the Bi-Specific MAbS Market and Drive Its Revenue Growth?

The bi-specific MAbS market covered in this report is segmented –

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp

Which Regions Are Emerging as Leaders in the Bi-Specific MAbS Market?

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Global Bi-Specific MAbS Market 2025, By The Business Research Company:

Microbiome Therapeutics Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Anti-Hypertensive Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Digital Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: